Adaptimmune Therapeutics
ADAP
$1.14
Share price
12.87%
Change (1 day)
-17.39%
Change (1 year)
Categories
Earnings for Adaptimmune Therapeutics (ADAP)
Earnings in 2023 (TTM): -$0.14 B
According to Adaptimmune Therapeutics's latest financial reports the company's current earnings (TTM) are -$0.14 B. In 2022 the company made an earning of -$0.17 B an increase over its 2021 earnings that were of -$0.17 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for Adaptimmune Therapeutics from 2016 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | -$0.14 B | -14.62% |
| 2022 | -$0.17 B | -0.36% |
| 2021 | -$0.17 B | 21.62% |
| 2020 | -$0.14 B | -4.55% |
| 2019 | -$0.14 B | 69% |
| 2018 | -$82.71 M | -7.47% |
| 2017 | -$89.39 M | 24.71% |
| 2016 | -$71.68 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 uniQure QURE | -$0.31 B | 122.08% | 🇳🇱 Netherlands |
 Novavax NVAX | -$0.53 B | 282.95% | 🇺🇸 USA |
 Exelixis EXEL | $0.25 B | -286.56% | 🇺🇸 USA |
 Enzo Biochem ENZ | -$9.61 M | -93.04% | 🇺🇸 USA |